Physician profile
Erin E Micklinghoff
NPI 1356694335
$5,909.70
in general payments reported to CMS, 2019-2025
26 companies · $1,923 in 2025
The $1,923 reported for 2025 was more than what 93% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $185 · 2022: $715 · 2023: $1,511 · 2024: $1,576 · 2025: $1,923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,890 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,889.78 |
| Education | $119.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,171.44 | 2021-2025 | Tremfya, Stelara, Remicade |
| Abbvie INC. | $997.11 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $515.98 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $394.69 | 2021-2025 | Xifaxan, Trulance |
| Celgene Corporation | $375.77 | 2023-2024 | Zeposia |
| Genzyme Corporation | $332.46 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $329.68 | 2022-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $179.83 | 2021-2025 | Rebyota, Clenpiq |
| Madrigal Pharmaceuticals | $176.96 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $168.69 | 2024-2025 | |
| Ardelyx, INC. | $163.51 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $155.04 | 2023-2025 | Sucraid, Sucraid |
| Vivus LLC | $145.49 | 2023-2025 | Pancreaze |
| Phathom Pharmaceuticals, INC. | $140.16 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $115.65 | 2024-2025 | Vegzelma, Zymfentra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $112.57 | 2022-2025 | Suflave, Sutab |
| Ironwood Pharmaceuticals, INC | $81.98 | 2021-2024 | Linzess |
| Ipsen Biopharmaceuticals, INC | $60.16 | 2025 | Iqirvo |
| Sandoz INC. | $57.91 | 2023-2024 | Hyrimoz |
| Aimmune Therapeutics, INC. | $52.16 | 2024 | |
| Merck Sharp & Dohme LLC | $43.28 | 2024 | Dificid |
| Evoke Pharma, INC. | $42.09 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $36.36 | 2022 | |
| Pfizer INC. | $24.81 | 2022 | |
| Mauna Kea Technologies, INC. | $18.13 | 2025 | |
| Organon LLC | $17.79 | 2023 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Micklinghoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.